- TRUP Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing
Trupanion (TRUP) 8-K2024 Q3 Trupanion Reports Third Quarter 2024 Results
Filed: 30 Oct 24, 4:02pm
Trupanion, Inc. Condensed Consolidated Statements of Operations (in thousands, except share data) | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Revenue: | |||||||||||||||||||||||
Subscription business | $ | 218,986 | $ | 182,906 | $ | 628,738 | $ | 521,369 | |||||||||||||||
Other business | 108,470 | 102,947 | 319,639 | 291,379 | |||||||||||||||||||
Total revenue | 327,456 | 285,853 | 948,377 | 812,748 | |||||||||||||||||||
Cost of revenue: | |||||||||||||||||||||||
Subscription business(1) | 177,365 | 157,444 | 525,237 | 455,055 | |||||||||||||||||||
Other business | 100,712 | 93,176 | 297,265 | 266,741 | |||||||||||||||||||
Total cost of revenue(2) | 278,077 | 250,620 | 822,502 | 721,796 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Technology and development(1) | 7,933 | 5,302 | 23,083 | 15,434 | |||||||||||||||||||
General and administrative(1) | 16,977 | 12,664 | 46,903 | 46,817 | |||||||||||||||||||
New pet acquisition expense(1) | 18,308 | 17,772 | 53,025 | 60,183 | |||||||||||||||||||
Depreciation and amortization | 4,381 | 2,990 | 12,542 | 9,445 | |||||||||||||||||||
Total operating expenses | 47,599 | 38,728 | 135,553 | 131,879 | |||||||||||||||||||
Gain (loss) from investment in joint venture | (34) | 4 | (184) | (140) | |||||||||||||||||||
Operating income (loss) | 1,746 | (3,491) | (9,862) | (41,067) | |||||||||||||||||||
Interest expense | 3,820 | 3,053 | 11,071 | 8,380 | |||||||||||||||||||
Other income, net | (3,538) | (2,465) | (9,601) | (6,445) | |||||||||||||||||||
Income (loss) before income taxes | 1,464 | (4,079) | (11,332) | (43,002) | |||||||||||||||||||
Income tax expense (benefit) | 39 | (43) | (43) | (472) | |||||||||||||||||||
Net income (loss) | $ | 1,425 | $ | (4,036) | $ | (11,289) | $ | (42,530) | |||||||||||||||
Net income (loss) per share: | |||||||||||||||||||||||
Basic | $ | 0.03 | $ | (0.10) | $ | (0.27) | $ | (1.03) | |||||||||||||||
Diluted | $ | 0.03 | $ | (0.10) | $ | (0.27) | $ | (1.03) | |||||||||||||||
Weighted average shares of common stock outstanding: | |||||||||||||||||||||||
Basic | 42,233,903 | 41,536,575 | 42,076,998 | 41,344,195 | |||||||||||||||||||
Diluted | 42,822,505 | 41,536,575 | 42,076,998 | 41,344,195 | |||||||||||||||||||
(1)Includes stock-based compensation expense as follows: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Cost of revenue | $ | 1,401 | $ | 1,176 | $ | 4,186 | $ | 3,801 | |||||||||||||||
Technology and development | 1,259 | 650 | 3,774 | 1,985 | |||||||||||||||||||
General and administrative | 4,125 | 3,281 | 11,435 | 14,448 | |||||||||||||||||||
New pet acquisition expense | 1,555 | 1,785 | 5,743 | 5,626 | |||||||||||||||||||
Total stock-based compensation expense | $ | 8,340 | $ | 6,892 | $ | 25,138 | $ | 25,860 | |||||||||||||||
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Veterinary invoice expense | $ | 238,814 | $ | 212,441 | $ | 703,485 | $ | 613,316 | |||||||||||||||
Other cost of revenue | 39,263 | 38,179 | 119,017 | 108,480 | |||||||||||||||||||
Total cost of revenue | $ | 278,077 | $ | 250,620 | $ | 822,502 | $ | 721,796 |
Trupanion, Inc. Condensed Consolidated Balance Sheets (in thousands, except share data) | |||||||||||
September 30, 2024 | December 31, 2023 | ||||||||||
(unaudited) | |||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 137,477 | $ | 147,501 | |||||||
Short-term investments | 155,580 | 129,667 | |||||||||
Accounts and other receivables, net of allowance for doubtful accounts of $1,015 at September 30, 2024 and $1,085 at December 31, 2023 | 289,823 | 267,899 | |||||||||
Prepaid expenses and other assets | 16,692 | 17,022 | |||||||||
Total current assets | 599,572 | 562,089 | |||||||||
Restricted cash | 23,394 | 22,963 | |||||||||
Long-term investments | 14,215 | 12,866 | |||||||||
Property, equipment and internal-use software, net | 102,862 | 103,650 | |||||||||
Intangible assets, net | 14,888 | 18,745 | |||||||||
Other long-term assets | 16,004 | 18,922 | |||||||||
Goodwill | 45,183 | 43,713 | |||||||||
Total assets | $ | 816,118 | $ | 782,948 | |||||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 10,136 | $ | 10,505 | |||||||
Accrued liabilities and other current liabilities | 33,461 | 34,052 | |||||||||
Reserve for veterinary invoices | 56,668 | 63,238 | |||||||||
Deferred revenue | 260,238 | 235,329 | |||||||||
Long-term debt - current portion | 1,350 | 1,350 | |||||||||
Total current liabilities | 361,853 | 344,474 | |||||||||
Long-term debt | 127,548 | 127,580 | |||||||||
Deferred tax liabilities | 2,166 | 2,685 | |||||||||
Other liabilities | 4,376 | 4,487 | |||||||||
Total liabilities | 495,943 | 479,226 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 43,368,881 and 42,340,695 issued and outstanding at September 30, 2024; 42,887,052 and 41,858,866 shares issued and outstanding at December 31, 2023 | — | — | |||||||||
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding | — | — | |||||||||
Additional paid-in capital | 561,010 | 536,108 | |||||||||
Accumulated other comprehensive income (loss) | 3,243 | 403 | |||||||||
Accumulated deficit | (227,544) | (216,255) | |||||||||
Treasury stock, at cost: 1,028,186 shares at September 30, 2024 and December 31, 2023 | (16,534) | (16,534) | |||||||||
Total stockholders’ equity | 320,175 | 303,722 | |||||||||
Total liabilities and stockholders’ equity | $ | 816,118 | $ | 782,948 |
Trupanion, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Operating activities | |||||||||||||||||||||||
Net income (loss) | $ | 1,425 | $ | (4,036) | $ | (11,289) | $ | (42,530) | |||||||||||||||
Adjustments to reconcile net loss to cash provided by (used in) operating activities: | |||||||||||||||||||||||
Depreciation and amortization | 4,381 | 2,990 | 12,542 | 9,445 | |||||||||||||||||||
Stock-based compensation expense | 8,341 | 6,892 | 25,138 | 25,860 | |||||||||||||||||||
Other, net | (136) | (549) | (453) | (1,134) | |||||||||||||||||||
Changes in operating assets and liabilities: | |||||||||||||||||||||||
Accounts and other receivables | (3,794) | (12,409) | (22,020) | (45,593) | |||||||||||||||||||
Prepaid expenses and other assets | 101 | 452 | 2,398 | (2,761) | |||||||||||||||||||
Accounts payable, accrued liabilities, and other liabilities | 1,377 | 2,632 | (350) | (3,832) | |||||||||||||||||||
Reserve for veterinary invoices | (3,934) | 5,258 | (6,469) | 17,697 | |||||||||||||||||||
Deferred revenue | 7,535 | 10,168 | 25,088 | 43,979 | |||||||||||||||||||
Net cash provided by (used in) operating activities | 15,296 | 11,398 | 24,585 | 1,131 | |||||||||||||||||||
Investing activities | |||||||||||||||||||||||
Purchases of investment securities | (26,125) | (29,458) | (107,375) | (109,389) | |||||||||||||||||||
Maturities and sales of investment securities | 26,089 | 29,713 | 81,767 | 147,365 | |||||||||||||||||||
Purchases of property, equipment, and internal-use software | (1,914) | (4,391) | (7,858) | (14,310) | |||||||||||||||||||
Other | 490 | 837 | 1,552 | 1,420 | |||||||||||||||||||
Net cash provided by (used in) investing activities | (1,460) | (3,299) | (31,914) | 25,086 | |||||||||||||||||||
Financing activities | |||||||||||||||||||||||
Proceeds from debt financing, net of financing fees | — | 24,972 | — | 60,102 | |||||||||||||||||||
Proceeds from exercise of stock options | 258 | 628 | 729 | 1,281 | |||||||||||||||||||
Shares withheld to satisfy tax withholding | (802) | (272) | (1,390) | (1,296) | |||||||||||||||||||
Repayments of debt financing | (338) | (338) | (1,013) | (1,380) | |||||||||||||||||||
Other financing | (157) | (150) | (609) | (150) | |||||||||||||||||||
Net cash provided by (used in) financing activities | (1,039) | 24,840 | (2,283) | 58,557 | |||||||||||||||||||
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | 481 | (906) | 19 | (830) | |||||||||||||||||||
Net change in cash, cash equivalents, and restricted cash | 13,278 | 32,033 | (9,593) | 83,944 | |||||||||||||||||||
Cash, cash equivalents, and restricted cash at beginning of period | 147,593 | 136,548 | 170,464 | 84,637 | |||||||||||||||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 160,871 | $ | 168,581 | $ | 160,871 | $ | 168,581 |
The following tables set forth our key operating metrics. | |||||||||||||||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||||||||||||||
Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total pets enrolled (at period end) | 1,688,903 | 1,712,177 | |||||||||||||||||||||||||||||||||||||||||||||
Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total subscription pets enrolled (at period end) | 1,032,042 | 969,322 | |||||||||||||||||||||||||||||||||||||||||||||
Monthly average revenue per pet | $ | 71.94 | $ | 64.63 | |||||||||||||||||||||||||||||||||||||||||||
Lifetime value of a pet, including fixed expenses | $ | 493 | $ | 428 | |||||||||||||||||||||||||||||||||||||||||||
Average pet acquisition cost (PAC) | $ | 227 | $ | 232 | |||||||||||||||||||||||||||||||||||||||||||
Average monthly retention | 98.29 | % | 98.55 | % | |||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||
Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total pets enrolled (at period end) | 1,688,903 | 1,699,643 | 1,708,017 | 1,714,473 | 1,712,177 | 1,679,659 | 1,616,865 | 1,537,573 | |||||||||||||||||||||||||||||||||||||||
Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total subscription pets enrolled (at period end) | 1,032,042 | 1,020,934 | 1,006,168 | 991,426 | 969,322 | 943,958 | 906,369 | 869,862 | |||||||||||||||||||||||||||||||||||||||
Monthly average revenue per pet | $ | 74.27 | $ | 71.72 | $ | 69.79 | $ | 67.07 | $ | 65.82 | $ | 64.41 | $ | 63.58 | $ | 63.11 | |||||||||||||||||||||||||||||||
Lifetime value of a pet, including fixed expenses | $ | 493 | $ | 450 | $ | 428 | $ | 419 | $ | 428 | $ | 470 | $ | 541 | $ | 641 | |||||||||||||||||||||||||||||||
Average pet acquisition cost (PAC) | $ | 243 | $ | 231 | $ | 207 | $ | 217 | $ | 212 | $ | 236 | $ | 247 | $ | 283 | |||||||||||||||||||||||||||||||
Average monthly retention | 98.29 | % | 98.34 | % | 98.41 | % | 98.49 | % | 98.55 | % | 98.61 | % | 98.65 | % | 98.69 | % |
The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands): | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Net cash provided by operating activities | $ | 15,296 | $ | 11,398 | $ | 24,585 | $ | 1,131 | |||||||||||||||
Purchases of property, equipment, and internal-use software | (1,914) | (4,391) | (7,858) | (14,310) | |||||||||||||||||||
Free cash flow | $ | 13,382 | $ | 7,007 | $ | 16,727 | $ | (13,179) |
The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands except percentages): | ||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
Veterinary invoice expense | $ | 238,814 | $ | 212,441 | $ | 703,485 | $ | 613,316 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense(1) | (830) | (870) | (2,535) | (2,565) | ||||||||||||||||||||||
Other business cost of paying veterinary invoices(4) | (82,507) | (72,694) | (239,342) | (210,286) | ||||||||||||||||||||||
Subscription cost of paying veterinary invoices (non-GAAP) | $ | 155,477 | $ | 138,877 | $ | 461,608 | $ | 400,465 | ||||||||||||||||||
% of subscription revenue | 71.0 | % | 75.9 | % | 73.4 | % | 76.8 | % | ||||||||||||||||||
Other cost of revenue | $ | 39,263 | $ | 38,179 | $ | 119,017 | $ | 108,480 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense(1) | (536) | (282) | (1,479) | (1,158) | ||||||||||||||||||||||
Other business variable expenses(4) | (18,126) | (20,482) | (57,713) | (56,455) | ||||||||||||||||||||||
Subscription variable expenses (non-GAAP) | $ | 20,601 | $ | 17,415 | $ | 59,825 | $ | 50,867 | ||||||||||||||||||
% of subscription revenue | 9.4 | % | 9.5 | % | 9.5 | % | 9.8 | % | ||||||||||||||||||
Technology and development expense | $ | 7,933 | $ | 5,302 | $ | 23,083 | $ | 15,434 | ||||||||||||||||||
General and administrative expense | 16,977 | 12,664 | 46,903 | 46,817 | ||||||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense(1) | (5,258) | (3,754) | (14,465) | (16,072) | ||||||||||||||||||||||
Non-recurring transaction or restructuring expenses(2) | — | (8) | — | (4,175) | ||||||||||||||||||||||
Development expenses(3) | (1,474) | (1,594) | (4,307) | (3,417) | ||||||||||||||||||||||
Fixed expenses (non-GAAP) | $ | 18,178 | $ | 12,610 | $ | 51,214 | $ | 38,587 | ||||||||||||||||||
% of total revenue | 5.6 | % | 4.4 | % | 5.4 | % | 4.7 | % | ||||||||||||||||||
New pet acquisition expense | $ | 18,308 | $ | 17,772 | $ | 53,025 | $ | 60,183 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense(1) | (1,503) | (1,679) | (5,426) | (5,433) | ||||||||||||||||||||||
Other business pet acquisition expense(4) | (8) | (10) | (31) | (123) | ||||||||||||||||||||||
Subscription acquisition cost (non-GAAP) | $ | 16,797 | $ | 16,083 | $ | 47,568 | $ | 54,627 | ||||||||||||||||||
% of subscription revenue | 7.7 | % | 8.8 | % | 7.6 | % | 10.5 | % | ||||||||||||||||||
(1) Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2024, respectively. (2) Consists of business acquisition transaction expenses, severance and legal costs due to certain executive departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. (3) Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant. (4) Excludes the portion of stock-based compensation expense attributable to the other business segment. | ||||||||||||||||||||||||||
The following table reflects the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages): | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Operating income (loss) | $ | 1,746 | $ | (3,491) | $ | (9,862) | $ | (41,067) | |||||||||||||||
Non-GAAP expense adjustments | |||||||||||||||||||||||
Acquisition cost | 16,805 | 16,093 | 47,599 | 54,750 | |||||||||||||||||||
Stock-based compensation expense(1) | 8,127 | 6,585 | 23,905 | 25,228 | |||||||||||||||||||
Development expenses(3) | 1,474 | 1,594 | 4,307 | 3,417 | |||||||||||||||||||
Depreciation and amortization | 4,381 | 2,990 | 12,542 | 9,445 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses(2) | — | 8 | — | 4,175 | |||||||||||||||||||
Gain (loss) from investment in joint venture | (34) | 4 | (184) | (140) | |||||||||||||||||||
Total adjusted operating income (non-GAAP) | $ | 32,567 | $ | 23,775 | $ | 78,675 | $ | 56,088 | |||||||||||||||
Subscription Business: | |||||||||||||||||||||||
Subscription operating income (loss) | $ | 3,824 | $ | (5,709) | $ | (4,109) | $ | (37,294) | |||||||||||||||
Non-GAAP expense adjustments | |||||||||||||||||||||||
Acquisition cost | 16,797 | 16,083 | 47,568 | 54,627 | |||||||||||||||||||
Stock-based compensation expense(1) | 6,215 | 4,996 | 18,723 | 19,229 | |||||||||||||||||||
Development expenses(3) | 986 | 1,257 | 2,855 | 2,439 | |||||||||||||||||||
Depreciation and amortization | 2,929 | 1,913 | 8,315 | 6,060 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses(2) | — | 5 | — | 223 | |||||||||||||||||||
Subscription adjusted operating income (non-GAAP) | $ | 30,751 | $ | 18,545 | $ | 73,352 | $ | 45,284 | |||||||||||||||
Other Business: | |||||||||||||||||||||||
Other business operating income (loss) | $ | (2,044) | $ | 2,214 | $ | (5,569) | $ | (3,633) | |||||||||||||||
Non-GAAP expense adjustments | |||||||||||||||||||||||
Acquisition cost | 8 | 10 | 31 | 123 | |||||||||||||||||||
Stock-based compensation expense(1) | 1,912 | 1,589 | 5,182 | 5,999 | |||||||||||||||||||
Development expenses(3) | 488 | 337 | 1,452 | 978 | |||||||||||||||||||
Depreciation and amortization | 1,452 | 1,077 | 4,227 | 3,385 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses(2) | — | 3 | — | 3,952 | |||||||||||||||||||
Other business adjusted operating income (non-GAAP) | $ | 1,816 | $ | 5,230 | $ | 5,323 | $ | 10,804 | |||||||||||||||
(1) Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation in accordance with GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2024, respectively. | |||||||||||||||||||||||
(2) Consists of business acquisition transaction expenses, severance and legal costs due to certain executive departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. | |||||||||||||||||||||||
(3) Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant. |
The following table reflects the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages): | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Subscription revenue | $ | 218,986 | $ | 182,906 | $ | 628,738 | $ | 521,369 | |||||||||||||||
Subscription cost of paying veterinary invoices | 155,477 | 138,877 | 461,608 | 400,465 | |||||||||||||||||||
Subscription variable expenses | 20,601 | 17,415 | 59,825 | 50,867 | |||||||||||||||||||
Subscription fixed expenses* | 12,157 | 8,069 | 33,953 | 24,753 | |||||||||||||||||||
Subscription adjusted operating income (non-GAAP) | $ | 30,751 | $ | 18,545 | $ | 73,352 | $ | 45,284 | |||||||||||||||
Other business revenue | 108,470 | 102,947 | $ | 319,639 | $ | 291,379 | |||||||||||||||||
Other business cost of paying veterinary invoices | 82,507 | 72,694 | 239,342 | 210,286 | |||||||||||||||||||
Other business variable expenses | 18,126 | 20,482 | 57,713 | 56,455 | |||||||||||||||||||
Other business fixed expenses* | 6,021 | 4,541 | 17,261 | 13,834 | |||||||||||||||||||
Other business adjusted operating income (non-GAAP) | $ | 1,816 | $ | 5,230 | $ | 5,323 | $ | 10,804 | |||||||||||||||
Revenue | 327,456 | 285,853 | $ | 948,377 | $ | 812,748 | |||||||||||||||||
Cost of paying veterinary invoices | 237,984 | 211,571 | 700,950 | 610,751 | |||||||||||||||||||
Variable expenses | 38,727 | 37,897 | 117,538 | 107,322 | |||||||||||||||||||
Fixed expenses* | 18,178 | 12,610 | 51,214 | 38,587 | |||||||||||||||||||
Total business adjusted operating income (non-GAAP) | $ | 32,567 | $ | 23,775 | $ | 78,675 | $ | 56,088 | |||||||||||||||
As a percentage of revenue: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Subscription revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Subscription cost of paying veterinary invoices | 71.0 | % | 75.9 | % | 73.4 | % | 76.8 | % | |||||||||||||||
Subscription variable expenses | 9.4 | % | 9.5 | % | 9.5 | % | 9.8 | % | |||||||||||||||
Subscription fixed expenses* | 5.6 | % | 4.4 | % | 5.4 | % | 4.7 | % | |||||||||||||||
Subscription adjusted operating income (non-GAAP) | 14.0 | % | 10.1 | % | 11.7 | % | 8.7 | % | |||||||||||||||
Other business revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Other business cost of paying veterinary invoices | 76.1 | % | 70.6 | % | 74.9 | % | 72.2 | % | |||||||||||||||
Other business variable expenses | 16.7 | % | 19.9 | % | 18.1 | % | 19.4 | % | |||||||||||||||
Other business fixed expenses* | 5.6 | % | 4.4 | % | 5.4 | % | 4.7 | % | |||||||||||||||
Other business adjusted operating income (non-GAAP) | 1.7 | % | 5.1 | % | 1.7 | % | 3.7 | % | |||||||||||||||
Revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Cost of paying veterinary invoices | 72.7 | % | 74.0 | % | 73.9 | % | 75.1 | % | |||||||||||||||
Variable expenses | 11.8 | % | 13.3 | % | 12.4 | % | 13.2 | % | |||||||||||||||
Fixed expenses* | 5.6 | % | 4.4 | % | 5.4 | % | 4.7 | % | |||||||||||||||
Total business adjusted operating income (non-GAAP) | 9.9 | % | 8.3 | % | 8.3 | % | 6.9 | % | |||||||||||||||
*Fixed expenses represent shared services that support both our subscription and other business segments and, as such, are generally allocated to each segment pro-rata based on revenues. |
The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ | (11,289) | $ | (42,530) | |||||||||||||||||||||||||||||||||||||||||||
Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 23,906 | 25,228 | |||||||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense | 12,542 | 9,445 | |||||||||||||||||||||||||||||||||||||||||||||
Interest income | (9,412) | (6,169) | |||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 11,071 | 8,380 | |||||||||||||||||||||||||||||||||||||||||||||
Other non-operating expenses | — | — | |||||||||||||||||||||||||||||||||||||||||||||
Income tax benefit | (43) | (472) | |||||||||||||||||||||||||||||||||||||||||||||
Non-recurring transaction or restructuring expenses | — | 4,175 | |||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss from equity method investment | (33) | (110) | |||||||||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 26,742 | $ | (2,053) | |||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||
Net income (loss) | $ | 1,425 | $ | (5,862) | $ | (6,852) | $ | (2,163) | $ | (4,036) | $ | (13,714) | $ | (24,780) | $ | (9,285) | |||||||||||||||||||||||||||||||
Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 8,127 | 8,381 | 7,398 | 6,636 | 6,585 | 6,503 | 12,140 | 8,412 | |||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense | 4,381 | 4,376 | 3,785 | 3,029 | 2,990 | 3,253 | 3,202 | 2,897 | |||||||||||||||||||||||||||||||||||||||
Interest income | (3,232) | (3,135) | (3,045) | (2,842) | (2,389) | (2,051) | (1,729) | (1,614) | |||||||||||||||||||||||||||||||||||||||
Interest expense | 3,820 | 3,655 | 3,596 | 3,697 | 3,053 | 2,940 | 2,387 | 1,587 | |||||||||||||||||||||||||||||||||||||||
Other non-operating expenses | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Income tax expense (benefit) | 39 | (44) | (38) | 130 | (43) | (238) | (191) | (15) | |||||||||||||||||||||||||||||||||||||||
Non-recurring transaction or restructuring expenses | — | — | 8 | 65 | 4,102 | 193 | |||||||||||||||||||||||||||||||||||||||||
(Gain) loss from equity method investment | (33) | — | (110) | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 14,527 | $ | 7,371 | $ | 4,844 | $ | 8,487 | $ | 6,058 | $ | (3,242) | $ | (4,869) | $ | 2,175 | |||||||||||||||||||||||||||||||